235 related articles for article (PubMed ID: 28981395)
1. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease.
Fabiani C; Sota J; Rigante D; Vitale A; Emmi G; Vannozzi L; Franceschini R; Bacherini D; Frediani B; Galeazzi M; Tosi GM; Cantarini L
Ocul Immunol Inflamm; 2019; 27(1):58-63. PubMed ID: 28981395
[TBL] [Abstract][Full Text] [Related]
2. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.
Keino H; Okada AA; Watanabe T; Taki W
Eye (Lond); 2014 Sep; 28(9):1100-6. PubMed ID: 24946845
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
Celiker H; Kazokoglu H; Direskeneli H
Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
[TBL] [Abstract][Full Text] [Related]
7. Ultra-Widefield Fluorescein Angiography to Monitor Therapeutic Response to Adalimumab in Behcet's Uveitis.
Kim BH; Park UC; Park SW; Yu HG
Ocul Immunol Inflamm; 2022 Aug; 30(6):1347-1353. PubMed ID: 33793368
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
[TBL] [Abstract][Full Text] [Related]
9. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features of patients with Behcet's uveitis].
Liu XS; Gao F; Zhao C; Zhang MF
Zhonghua Yan Ke Za Zhi; 2020 Mar; 56(3):217-223. PubMed ID: 32187951
[No Abstract] [Full Text] [Related]
13. Efficacy of golimumab in patients with refractory non-infectious panuveitis.
Tungsattayathitthan U; Tesavibul N; Choopong P; Treeratsakulchai C; Ngathaweesuk Y; Sanphan W; Boonsopon S
Sci Rep; 2024 Jan; 14(1):2179. PubMed ID: 38273077
[TBL] [Abstract][Full Text] [Related]
14. Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Behçet's disease.
Ishikawa S; Taguchi M; Muraoka T; Sakurai Y; Kanda T; Takeuchi M
Br J Ophthalmol; 2014 Nov; 98(11):1508-13. PubMed ID: 24939422
[TBL] [Abstract][Full Text] [Related]
15. Pattern and causes of visual loss in Behçet's uveitis: short-term and long-term outcomes.
Amer R; Alsughayyar W; Almeida D
Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1423-1432. PubMed ID: 28396946
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study.
Tugal-Tutkun I; Kadayifcilar S; Khairallah M; Lee SC; Ozdal P; Özyazgan Y; Song JH; Yu HG; Lehner V; de Cordoue A; Bernard O; Gül A
Ocul Immunol Inflamm; 2017 Feb; 25(1):62-70. PubMed ID: 26829647
[TBL] [Abstract][Full Text] [Related]
17. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.
Martín-Varillas JL; Calvo-Río V; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Garfella MH; Pascual EV; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; Salom D; Ortego N; García-Serrano JL; Callejas-Rubio JL; Herreras JM; García-Aparicio Á; Maíz O; Blanco A; Torre I; Díaz-Valle D; Pato E; Aurrecoechea E; Caracuel MA; Gamero F; Minguez E; Carrasco-Cubero C; Olive A; Vázquez J; Ruiz-Moreno O; Manero J; Muñoz-Fernández S; Martinez MG; Rubio-Romero E; Toyos-Sáenz de Miera FJ; López Longo FJ; Nolla JM; Revenga M; González-Vela C; Loricera J; Atienza-Mateo B; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Ophthalmology; 2018 Sep; 125(9):1444-1451. PubMed ID: 29602570
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal Dexamethasone Implant as an Adjunct Weapon for Severe and Refractory Uveitis in Behçet's Disease.
Fabiani C; Emmi G; Lopalco G; Vannozzi L; Bacherini D; Guerriero S; Franceschini R; Frediani B; Iannone F; Marco Tosi G; Rigante D; Cantarini L
Isr Med Assoc J; 2017 Jul; 19(7):415-419. PubMed ID: 28786255
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
Gül A; Tugal-Tutkun I; Dinarello CA; Reznikov L; Esen BA; Mirza A; Scannon P; Solinger A
Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis.
Yang S; Huang Z; Liu X; Li H; Xie L; Chen X; Wen F; Liang D; Su W
Int Immunopharmacol; 2021 Apr; 93():107430. PubMed ID: 33581500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
